HeartBeam Inc. (NASDAQ: BEAT), a medical technology company specializing in cardiac care solutions, has announced a commercial agreement with Atelier Health, a Beverly Hills-based concierge medical practice. This partnership expands HeartBeam's launch footprint into Southern California, completing the company's initial targeted markets alongside New York metro, Dallas, and South Florida. The agreement marks a significant step in the commercialization of HeartBeam's cable-free 3D ECG technology for remote cardiac monitoring and preventive cardiology.
HeartBeam is developing the first-ever cable-free device capable of collecting ECG signals in 3D from three non-coplanar directions and synthesizing them into a 12-lead ECG. This platform technology is designed for portable devices that can be used wherever the patient is, delivering actionable heart intelligence. Physicians using the technology can identify cardiac health trends and acute conditions, directing patients to appropriate care outside of a medical facility. This approach aims to redefine the future of cardiac health management.
HeartBeam's 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024, and the 12-lead ECG synthesis software received clearance in December 2025. The company holds over 20 issued patents related to technology enablement. The expansion into Southern California through the Atelier Health agreement is expected to provide patients in the region with access to advanced remote cardiac monitoring capabilities, potentially improving early detection and management of heart conditions.
The partnership with Atelier Health, a concierge medical practice, highlights the growing trend of personalized, high-touch healthcare services integrating innovative technology. For the concierge cardiology sector, this agreement could set a precedent for adopting advanced remote monitoring tools, enhancing patient outcomes and convenience. For the broader healthcare industry, HeartBeam's technology represents a shift toward more accessible and continuous cardiac care outside traditional clinical settings.
As HeartBeam continues its commercial rollout, the completion of its initial targeted markets positions the company to scale its operations and potentially expand further. The implications for patients include reduced need for frequent hospital visits and more proactive management of cardiac health. For investors, the agreement signals progress in HeartBeam's commercialization strategy, which could influence the company's growth trajectory in the competitive medical technology landscape.
